Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
21.72B
Market cap21.72B
Price-Earnings ratio
-6.73
Price-Earnings ratio-6.73
Dividend yield
Dividend yield
Average volume
4.94M
Average volume4.94M
High today
$60.35
High today$60.35
Low today
$52.79
Low today$52.79
Open price
$57.85
Open price$57.85
Volume
7.76M
Volume7.76M
52 Week high
$85.60
52 Week high$85.60
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

Moderna(MRNA) stock is priced at $54.58, giving the company a market capitalization of 21.72B. It carries a P/E multiple of -6.73.

During the trading session on 2026-08-03, Moderna(MRNA) shares reached a daily high of $60.35 and a low of $52.79. At a current price of $54.58, the stock is +3.4% higher than the low and still -9.6% under the high.

Trading volume for Moderna(MRNA) stock has reached 7.76M, versus its average volume of 4.94M.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.

MRNA News

Simply Wall St 3h
Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?

In the past quarter, Moderna, Inc. reported second-quarter 2026 revenue of US$145 million versus US$142 million a year earlier, with a net loss of US$782 millio...

Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?
Simply Wall St 2d
Moderna Stock Looks Strong On Returns But Fully Priced On Sales

Moderna stock has delivered a strong 98.6% return over the past year, yet its broader valuation checks still lean expensive, so investors are weighing a sharp s...

Moderna Stock Looks Strong On Returns But Fully Priced On Sales
Benzinga 3d
Moderna Burns Cash, Suffers Fresh Vaccine Setback

The COVID-19 vaccine maker reported sales of $145 million, better than the Wall Street estimate of $102.998 million. Lower COVID vaccine sales in the U.S. and...

Moderna Burns Cash, Suffers Fresh Vaccine Setback

Analyst ratings

65%

of 26 ratings
Buy
19.2%
Hold
65.4%
Sell
15.4%

More MRNA News

TipRanks 3d
Moderna Wins a Post-COVID Earnings Beat as Analyst Eyes ‘Clinically Meaningful’ Trial Results

Moderna’s (MRNA) latest earnings were better-than-expected. Jefferies (JEF) analyst Andrew Tsai explained that while quarterly earnings beat expectations, new d...

Nasdaq 3d
Moderna Reports Q2 Loss, Tops Revenue Estimates

Moderna (MRNA) came out with a quarterly loss of $3.62 per share versus the Zacks Consensus Estimate of a loss of $3.84. This compares to earnings of $5.24 per...

Moderna Reports Q2 Loss, Tops Revenue Estimates
The Wall Street Journal 3d
Moderna Narrows Loss, Says New Norovirus Vaccine Didn’t Meet Expectations

Moderna narrowed its loss in the second quarter. Brian Snyder / Reuters Moderna MRNA 6.29 %increase; up pointing triangle narrowed its loss in the second quart...

Moderna Narrows Loss, Says New Norovirus Vaccine Didn’t Meet Expectations
Nasdaq 3d
Moderna, Inc Q2 Loss Decreases

(RTTNews) - Moderna, Inc (MRNA) released Loss for second quarter of -$782 million The company's earnings totaled -$782 million, or -$1.97 per share. This compa...

Moderna, Inc Q2 Loss Decreases
TipRanks 3d
Moderna sees FY26 cost of sales $1.7B, down from prior $1.8B view

The company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Mod...

Simply Wall St 4d
Moderna Beat Revenue Views, Is The Stock Now Too Expensive?

Moderna (MRNA) has been in focus after its recent quarter showed significant year over year revenue growth that beat market expectations, along with fresh Europ...

Moderna Beat Revenue Views, Is The Stock Now Too Expensive?
Nasdaq 7d
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

The second-quarter 2024 reporting cycle of the Medical sector will gain further traction this week. The sector mainly comprises pharma/biotech and medical devic...

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.